Be the first to like this
Drug delivery technology that could make a drug more effective and less harmful to patients.
Currently, about 30% of drugs that appear on the World Health Organization (WHO) Essential Drug List were reported to be poorly water-soluble, based on the Biopharmaceutics Classification System (BCS) .
Over 40% of newly developed pharmaceutically active substances have solubility issues.
The poor dissolution and/or permeability of these drugs often result in low and highly variable bioavailability.
The major obstacle of successfully commercializing these compounds is the difficulty of enhancing their dissolution rate and extent of dissolution
.In a word: bioavailability. As much as $40 billion is invested annually in drug discovery. Unfortunately, many of the drug leads that result exhibit poor water solubility and an inability to deliver therapeutic agents in vivo. In fact, it's estimated that 40-50 percent of these new chemical entities are poorly water soluble. (which leads to a number of otherwise promising technologies to be abandoned)
Despite the solubility issue, worldwide sales of poorly soluble drugs are about $108 billion and it is going to increase further. It is reasonably expected that improving water solubility would only increase this number.
The result is inefficiency in the R&D process. Due to the challenges of evaluating efficacy in biologic models for a poorly bio-available compound, these compounds are often shelved with no further development activity—even if they show promising therapeutic activity in cell culture.
Meda’s hybrid formulation technology addresses this problem by improving water solubility, bioavailability, effectiveness and efficiency.
Poor water solubility for many drugs and drug candidates remains a major obstacle to their development and clinical application. Conventional formulations to improve solubility suffer from low bioavailability and poor pharmacokinetics, with some carriers rendering systemic toxicities (e.g. Cremophor1 EL).
Scale. The process has been specifically developed to achieve commercial manufacturing scale.
Simplicity. The technology is unique in its simplicity as the process can be performed using normal manufacturing equipment that is present in most development and manufacturing facilities.
Cost & Increased Profitability. Because the development costs for new chemical entities are so high, many companies are instead working to optimize existing marketed molecules – this saves R&D expenses and should also have decreased drug approval costs.
This is perhaps the only available technology that delivers a synergistic and potentiating partnership with a soluble formulation.
Experience –More than 40 drugs
Creativity – A new approach from our discovery
Combining technology, experience, and creativity, Meda Biotech would like to explore the opportunities with you.